Gastrointestinal Endoscopic Devices Market: as computer-aided detection modules move from optional add-on to standard feature across every major colonoscope platform launch, the clinical question shaping GI device purchasing is narrowing from which manufacturer builds the sharpest image to which AI detection algorithm demonstrably lifts adenoma detection rate in a colonoscopist's own hands, so procurement committees increasingly need site-specific validation data before committing to a platform, and the advantage is moving toward vendors who can furnish that evidence fastest after launch.

The global gastrointestinal endoscopic devices market size was USD 12.42 Billion in 2025 and is expected to register a revenue CAGR of 6.2% during the forecast period. Market revenue growth is driven by factors such as sustained high-volume colonoscopy and colorectal cancer screening demand, computer-aided detection modules becoming standard rather than optional across new platform launches, and next-generation imaging system releases from the largest GI device manufacturers. The first driving factor is the sheer scale of colonoscopy procedure volume, with more than 14.2 million colonoscopies performed annually in the United States alone. Flexible GI endoscopes account for approximately 53% of total 2025 market revenue, reflecting how central the core scope hardware remains to overall GI device market value. The second driving factor is computer-aided detection modules becoming a standard platform feature rather than an optional add-on across new colonoscope and gastroscope launches. The third driving factor is a wave of next-generation imaging system releases from the largest GI device manufacturers competing on resolution and enhanced visualization technology. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single GI imaging platform accumulates additional AI detection modules and cleared indications over its installed lifetime, which converts one processor and scope tower purchase into a widening set of billable software and accessory attachments without a new capital equipment cycle. Once a hospital or ASC adopts a manufacturer's core GI visualization platform, each additional AI-enabled detection module cleared for use with that platform adds incremental software revenue to an already-installed system, so platform revenue compounds as a manufacturer's compatible AI module catalogue widens around the same processor architecture. As a result, demand and revenue share are concentrating around manufacturers with the broadest AI detection module catalogue compatible with their installed base, and the forecast tilts toward vendors who can extend an existing platform's software capability rather than those relying on new capital placements alone. For instance, in May 2025, Olympus received FDA 510(k) clearance for its EZ1500 series endoscopes featuring Extended Depth of Field technology, extending its EVIS X1 platform's imaging capability across an already-installed base of compatible GI colonoscopy and gastroscopy systems. These are some of the key factors driving revenue growth of the market.

Because each successive generation of flagship GI visualization platforms commands a meaningful price premium over the generation it replaces, hospital and ASC capital budgets face growing pressure to justify replacement-cycle timing against the incremental clinical benefit each new platform generation delivers.

Endoscopist capacity shortages are a second constraint, because colorectal cancer screening guideline expansion is adding eligible screening candidates faster than the supply of trained gastroenterologists can grow, which means new device capability alone cannot fully translate into expanded screening throughput without a corresponding increase in physician capacity.

Reprocessing infrastructure requirements are a third constraint, since reusable GI endoscopes require dedicated high-level disinfection infrastructure and trained reprocessing staff, and facilities without adequate reprocessing capacity face a real trade-off between reusable endoscope capital savings and the infection control risk that inadequate reprocessing can introduce.

These factors substantially limit gastrointestinal endoscopic devices market growth over the forecast period.

The clearest driver of demand is the sheer scale of colonoscopy procedure volume, with more than 14.2 million colonoscopies performed annually in the United States alone as a routine, guideline-recommended screening procedure. Colonoscopy remains the gold-standard colorectal cancer screening method in most clinical guidelines, so procedure volume tracks the screening-eligible population directly, providing a demand base that grows with demographic and guideline trends rather than depending on any single manufacturer's product cycle. Flexible GI endoscopes account for approximately 53% of total 2025 market revenue, and Olympus reported that its Endoscopic Solutions Division generated approximately JPY 636.1 billion in its most recent fiscal year, with North America contributing double-digit growth specifically attributed to its EVIS X1 platform performance. The effect on the market is that baseline GI endoscope demand remains structurally resilient even during periods of capital spending caution, because screening colonoscopy volume does not defer in the way discretionary procedures might. These are some of the key factors driving revenue growth of the market.

The second driver is the integration of computer-aided detection modules directly into new GI endoscopy platform launches, converting AI-assisted polyp detection from an optional add-on into a standard feature. Computer-aided detection has demonstrated measurable improvement in adenoma detection rates in clinical studies, so manufacturers building AI detection directly into new platform launches are responding to accumulating clinical evidence that AI-assisted detection materially improves screening quality, not simply adding a marketing differentiator. Medtronic unveiled its ColonPRO AI software for its GI Genius platform, and Olympus received FDA 510(k) clearance for its CADDIE cloud-based AI colonoscopy detection system before extending it with CE Mark clearance under the EU Medical Device Regulation alongside its CADU and SMARTIBD modules as part of its Intelligent Endoscopy Ecosystem. The effect on the market is that AI detection capability is becoming a baseline procurement expectation for new colonoscopy platform purchases rather than a premium differentiator commanding a separate price tier. These are some of the key factors driving revenue growth of the market.

Flexible GI endoscopes already account for approximately 53% of 2025 gastrointestinal endoscopic devices market revenue. AI detection capability is fast becoming the deciding factor in replacement-cycle purchasing, not imaging resolution alone.

The third driver is a wave of next-generation imaging system releases from the largest GI device manufacturers, each competing on resolution and enhanced visualization technology in close succession. Endoscopic detection accuracy depends heavily on image resolution and enhanced visualization modes that highlight subtle mucosal changes, so each successive imaging platform generation that measurably improves lesion detection creates a genuine clinical case for hospital and ASC replacement even on a compressed timeline. In October 2025, Fujifilm launched its ELUXEO 8000 Endoscopic Imaging System featuring a new Amber-Red Color Imaging mode compatible with the company's 500 through 800 series endoscopes, and Pentax Medical received FDA 510(k) clearance for its i20c video endoscope series featuring advanced imaging and improved ergonomics. The effect on the market is that hospital and ASC capital planning cycles are compressing as manufacturers release meaningful imaging improvements more frequently than in prior device generations. These are some of the key factors driving revenue growth of the market.

However, the gastrointestinal endoscopic devices market faces severe adoption constraints from high capital equipment replacement costs and endoscopist capacity shortages relative to expanding colorectal cancer screening demand.

Because each successive generation of flagship GI visualization platforms commands a meaningful price premium over the generation it replaces, hospital and ASC capital budgets face growing pressure to justify replacement-cycle timing against the incremental clinical benefit each new platform generation delivers, particularly as the pace of new platform releases accelerates.

Endoscopist capacity shortages compound this, because colorectal cancer screening guideline expansion is adding eligible screening candidates faster than the supply of trained gastroenterologists can grow, which means new device capability alone cannot fully translate into expanded screening throughput without a corresponding increase in physician capacity.

Reprocessing infrastructure requirements are the third constraint, since reusable GI endoscopes require dedicated high-level disinfection infrastructure and trained reprocessing staff, and facilities without adequate reprocessing capacity face a real trade-off between reusable endoscope capital savings and the infection control risk that inadequate reprocessing can introduce.

These factors substantially limit gastrointestinal endoscopic devices market growth over the forecast period.

Based on device type, the global gastrointestinal endoscopic devices market is segmented into flexible GI endoscopes, capsule endoscopes, visualization systems and processors, GI endotherapy accessories, and AI-assisted detection modules. Flexible GI endoscopes hold the largest revenue share, because the core gastroscope, colonoscope, and duodenoscope hardware represents the largest single capital purchase in any GI endoscopy programme, which suits a market where scope hardware still anchors the largest revenue category despite growing software and AI attach revenue. Capsule endoscopes remain a specialised category for small bowel evaluation and are individually higher-priced per unit but lower in overall volume than flexible scopes. AI-assisted detection modules are expected to register the fastest revenue growth rate in the global gastrointestinal endoscopic devices market over the forecast period, driven by AI capability increasingly shipping as a standard platform feature, which is why manufacturers continue to expand their AI-enabled module catalogues alongside core imaging hardware.

Colorectal cancer screening application is expected to account for the largest revenue share in the global gastrointestinal endoscopic devices market during the forecast period

Based on application, the global gastrointestinal endoscopic devices market is segmented into colorectal cancer screening, upper GI diagnostics and Barrett's surveillance, GI therapeutic intervention, and inflammatory bowel disease monitoring. Colorectal cancer screening holds the largest revenue share, because colonoscopy procedure volume dwarfs other GI endoscopy application categories globally, which ties directly back to the screening volume described in the market's primary demand driver. GI therapeutic intervention is expected to register the fastest revenue growth rate in the global gastrointestinal endoscopic devices market over the forecast period, driven by expanding endoscopic mucosal resection and submucosal dissection procedure adoption as alternatives to surgical intervention for early-stage GI lesions.

AI-assisted visualization technology tier is expected to register the fastest revenue growth rate in the global gastrointestinal endoscopic devices market during the forecast period

Based on technology, the global gastrointestinal endoscopic devices market is segmented into reusable HD and 4K endoscopy systems, single-use disposable endoscopes, and AI-assisted visualization technology. Reusable HD and 4K endoscopy systems hold the largest revenue share, because they remain the default technology tier across the majority of hospital and academic GI endoscopy programmes, which suits a market where established, high-resolution reusable platforms still anchor the largest revenue category. AI-assisted visualization technology is expected to register the fastest revenue growth rate in the global gastrointestinal endoscopic devices market over the forecast period, driven by CADe and CADx module integration into standard colonoscopy and gastroscopy workflows, which is why manufacturers are prioritising AI capability as a core platform differentiator.

Based on regional analysis, the gastrointestinal endoscopic devices market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of colonoscopy screening volume and FDA clearance activity creates a direct clinical-to-commercial pathway, and because Olympus, Boston Scientific, and Medtronic all maintain their primary commercial presence in the US market. Olympus specifically reported North America double-digit performance for its EVIS X1 platform, reflecting the depth of US replacement-cycle demand. The concentration of FDA clearance activity in the country also means new GI imaging platform generations are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Karl Storz, headquartered in Germany, maintains its primary global commercial and manufacturing base in Europe, and CE Mark approval frequently accompanies or precedes FDA clearance for GI platform extensions in this market. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan and China represent the two largest national markets within the region, with Japan serving as the primary manufacturing and R&D base for Olympus and Fujifilm. Olympus also launched its EVIS X1 platform in Brazil as part of its broader Latin American expansion, while China's rapidly expanding hospital colonoscopy capacity leaves considerably more room for growth than in the already platform-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with Olympus' EVIS X1 Brazil launch specifically targeting regional physician training and clinical adoption. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the precision optical and electronic components that Latin American device distributors depend on, an effect expected to run through 2026 and slow GI endoscopic device adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for GI endoscopic device adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist GI endoscopy infrastructure needed to support advanced imaging platforms at scale.